Liaisons dangereuses: P2X7 and the inflammasome

Trends in Pharmacological Sciences

Volumn 28, Issue 9, 2007, Pages 465-472

  Di Virgilio, Francesco ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1 [N,O BIS(5 ISOQUINOLINESULFONYL) N METHYLTYROSYL] 4 PHENYLPIPERAZINE; ACETAMIDE; ADAMANTANE DERIVATIVE; ADENOSINE TRIPHOSPHATE; ANTIINFLAMMATORY AGENT; BACTERIUM LIPOPOLYSACCHARIDE; BENZAMIDE; CASPASE; CYTOKINE; GAP JUNCTION PROTEIN; HELICASE; IMIDAZOLINE DERIVATIVE; IMIDE; INTERLEUKIN 18; INTERLEUKIN 1BETA; NEURONAL APOPTOSIS INHIBITORY PROTEIN; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PANNEXIN; PATTERN RECOGNITION RECEPTOR; PURINE P2X7 RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; RECEPTOR SUBTYPE; RETINOIC ACID INDUCIBLE GENE LIKE HELICASE; SCAFFOLD PROTEIN; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

CYTOKINE RELEASE; ENZYME ACTIVITY; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; INFECTION; INFLAMMATION; INNATE IMMUNITY; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN DOMAIN; REVIEW;

ADENOSINE TRIPHOSPHATE; ANIMALS; CARRIER PROTEINS; CASPASES; CONNEXINS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKIN-1BETA; NUCLEAR MATRIX-ASSOCIATED PROTEINS; RECEPTORS, PURINERGIC P2;

EID: 34548444551     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2007.07.002     Document Type: Review

References (77)

1. Janeway Jr. C.A., and Medzhitov R. Innate immune recognition. Annu. Rev. Immunol. 20 (2002) 197-216
2. Matzinger P. The danger model: a renewed sense of self. Science 296 (2002) 301-305
3. Meylan E., et al. Intracellular pattern recognition receptors in the host response. Nature 442 (2006) 39-44
4. Kornbluth R.S., and Stone G.W. Immunostimulatory combinations: designing the next generation of vaccine adjuvants. J. Leukoc. Biol. 80 (2006) 1084-1102
5. Di Virgilio F. Purinergic mechanism in the immune system: a signal of danger for dendritic cells. Purinergic Signaling 1 (2005) 205-209
6. Ferrari D., et al. Purinergic modulation of interleukin-1β release from microglial cells stimulated with bacterial endotoxin. J. Exp. Med. 185 (1997) 579-582
7. 7 receptor inhibition improves recovery after spinal cord injury. Nat. Med. 10 (2004) 821-827
8. Burnstock G. Pathophysiology and therapeutic potential of purinergic signaling. Pharmacol. Rev. 58 (2006) 58-86
9. Mizumoto N., et al. CD39 is the dominant Langerhans cell-associated ecto-NTPDase: modulatory roles in inflammation and immune responsiveness. Nat. Med. 8 (2002) 358-365
10. Eltzschig H.K., et al. ATP release from activated neutrophils occurs via connexin-43 and modulates adenosine-dependent endothelial cell function. Circ. Res. 99 (2006) 1100-1108
11. TranVan Nhieu G., et al. Calcium signalling during cell interactions with bacterial pathogens. Biol. Cell 96 (2004) 93-101
12. Crane J.K., et al. Two pathways for ATP release from host cells in enteropathogenic Escherichia coli infection. Am. J. Physiol. Gastrointest. Liver Physiol. 289 (2005) 407-417
13. Burnstock G. Historical review: ATP as a neurotransmitter. Trends Pharmacol. Sci. 27 (2006) 166-176
14. la Sala A., et al. Extracellular ATP induces a distorted maturation of dendritic cells and inhibits their capacity to initiate Th1 responses. J. Immunol. 166 (2001) 1611-1617
15. Wilkin F., et al. Extracellular adenine nucleotides modulate cytokine production by human monocyte-derived dendritic cells: dual effect on IL-12 and stimulation of IL-10. Eur. J. Immunol. 32 (2002) 2409-2417
16. la Sala A., et al. Alerting and tuning the immune response by extracellular nucleotides. J. Leukoc. Biol. 73 (2003) 339-343
17. Boeynaems J.M., and Communi D. Modulation of inflammation by extracellular nucleotides. J. Invest. Dermatol. 126 (2006) 943-944
18. Bours M.J., et al. Adenosine 5′-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol. Ther. 112 (2006) 358-404
19. Di Virgilio F. The P2Z purinoceptor: an intriguing role in immunity, inflammation and cell death. Immunol. Today 16 (1995) 524-528
20. 7). Science 272 (1996) 735-738
21. Sitkovsky M.V., and Ohta A. The 'danger' sensors that STOP the immune response: the A2 adenosine receptors? Trends Immunol. 26 (2005) 299-304
22. Sitkovsky M.V., et al. Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu. Rev. Immunol. 22 (2004) 657-682
23. 7 receptor: a key player in IL-1 processing and release. J. Immunol. 176 (2006) 3877-3883
24. Ferrari D., et al. Extracellular ATP triggers IL-1 beta release by activating the purinergic P2Z receptor of human macrophages. J. Immunol. 159 (1997) 1451-1458
25. 7 receptors. J. Biol. Chem. 276 (2001) 125-132
26. Dinarello C.A. The IL-1 family and inflammatory diseases. Clin. Exp. Rheumatol. 20 (2002) S1-S13
27. Martinon F., and Tschopp J. Inflammatory caspases: linking an intracellular innate immune system to autoinflammatory diseases. Cell 117 (2004) 561-574
28. Dinarello C.A. Unraveling the NALP-3/IL-1β inflammasome: a big lesson from a small mutation. Immunity 20 (2004) 243-244
29. Martinon F., et al. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-1β. Mol. Cell 10 (2002) 417-426
30. Zamboni D.S., et al. The Birc1e cytosolic pattern-recognition receptor contributes to the detection and control of Legionella pneumophila infection. Nat. Immunol. 7 (2006) 318-325
31. Martinon F., and Tschopp J. Inflammatory caspases and inflammasomes: master switches of inflammation. Cell Death Differ. 14 (2007) 10-22
32. Tschopp J., et al. NALPs: a novel protein family involved in inflammation. Nat. Rev. Mol. Cell Biol. 4 (2003) 95-104
33. Martinon F., et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440 (2006) 237-241
34. Mariathasan S., et al. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440 (2006) 228-232
35. Kanneganti T.D., et al. Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature 440 (2006) 233-236
36. Deveraux Q.L., et al. Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases. EMBO J. 18 (1999) 5242-5251
37. Ting J.P.Y., et al. CATERPILLERs, pyrin and hereditary immunological disorders. Nat. Rev. Immunol. 6 (2006) 183-195
38. Martinon F., and Tschopp J. NLRs join TLRs as innate sensors of pathogens. Trends Immunol. 26 (2005) 447-454
39. Faustin B., et al. Reconstituted NALP1 inflammasome reveals two-step mechanism of caspase-1 activation. Mol. Cell 25 (2007) 713-724
40. Boyden E.D., and Dietrich W.F. Nalp1b controls mouse macrophage susceptibility to anthrax lethal toxin. Nat. Genet. 38 (2006) 240-244
41. Franchi L., et al. Cytosolic flagellin requires Ipaf for activation of caspase-1 and interleukin 1β in salmonella-infected macrophages. Nat. Immunol. 7 (2006) 576-582
42. Ogura Y., et al. The inflammasome: first line of the immune response to cell stress. Cell 126 (2006) 659-662
43. Mariathasan S., et al. Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature 430 (2004) 213-218
44. Sutterwala F.S., et al. Critical role for NALP3/CIAS1/Cryopyrin in innate and adaptive immunity through its regulation of caspase-1. Immunity 24 (2006) 317-327
45. Sanz J.M., and Di Virgilio F. Kinetics and mechanism of ATP-dependent IL-1β release from microglial cells. J. Immunol. 164 (2000) 4893-4898
46. Dinarello C.A. Blocking IL-1 in systemic inflammation. J. Exp. Med. 201 (2005) 1355-1359
47. Gurcel L., et al. Caspase-1 activation of lipid metabolic pathways in response to bacterial pore-forming toxins promotes cell survival. Cell 126 (2006) 1135-1145
48. Cheneval D., et al. Increased mature interleukin-1β (IL-1β) secretion from THP-1 cells induced by nigericin is a result of activation of p45 IL-1beta-converting enzyme processing. J. Biol. Chem. 273 (1998) 17846-17851
49. + inhibit cytochrome c-dependent formation of the apoptosome. J. Biol. Chem. 276 (2001) 41985-41990
50. North R.A. Molecular physiology of P2X receptors. Physiol. Rev. 82 (2002) 1013-1067
51. Beyer E.C., and Steinberg T.H. Evidence that the gap junction protein connexin-43 is the ATP-induced pore of mouse macrophages. J. Biol. Chem. 266 (1991) 7971-7974
52. Coutinho-Silva R., and Persechini P.M. P2Z purinoceptor-associated pores induced by extracellular ATP in macrophages and J774 cells. Am. J. Physiol. 273 (1997) C1793-C1800
53. 7 receptor. EMBO J. 25 (2006) 5071-5082
54. Pelegrin P., and Surprenant A. Pannexin-1 couples to maitotoxin- and nigericin-induced interleukin-1β release through a dye uptake-independent pathway. J. Biol. Chem. 282 (2007) 2386-2394
55. 7 receptor death complex. FEBS Lett. 581 (2007) 483-488
56. Panchin Y., et al. A ubiquitous family of putative gap junction molecules. Curr. Biol. 10 (2000) R473-R474
57. Bruzzone R., et al. Pannexins, a family of gap junction proteins expressed in brain. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 13644-13649
58. Huang Y.J., et al. The role of pannexin-1 hemichannels in ATP release and cell-cell communication in mouse taste buds. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 6436-6441
59. Perregaux D., and Gabel C.A. Interleukin-1β maturation and release in response to ATP and nigericin. Evidence that potassium depletion mediated by these agents is a necessary and common feature of their activity. J. Biol. Chem. 269 (1994) 15195-15203
60. Andrei C., et al. Phospholipases C and A2 control lysosome-mediated IL-1β secretion: implications for inflammatory processes. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 9745-9750
61. MacKenzie A., et al. Rapid secretion of interleukin-1β by microvesicle shedding. Immunity 15 (2001) 825-835
62. Laliberte R.E., et al. ATP treatment of human monocytes promotes caspase-1 maturation and externalization. J. Biol. Chem. 274 (1999) 36944-36951
63. Pizzirani C., et al. Stimulation of P2 receptors causes release of IL-1β-loaded microvesicles from human dendritic cells. Blood 109 (2007) 3856-3864
64. Stojanov S., and Kastner D.L. Familial autoinflammatory diseases: genetics, pathogenesis and treatment. Curr Opin. Rheumatol. 17 (2005) 586-599
65. Murgia M., et al. Oxidized ATP. An irreversible inhibitor of the macrophage purinergic P2Z receptor. J. Biol Chem. 268 (1993) 8199-8203
66. Gever J.R., et al. Pharmacology of P2X channels. Pflugers Arch. 452 (2006) 513-537
67. 7 receptor. J. Med. Chem. 46 (2003) 1318-1329
68. 7 receptor modulators. US patent number 7094895
69. 7 receptors, AZ11645373. Br J. Pharmacol. 149 (2006) 880-887
70. 7 receptor antagonists Bioorg. Med. Chem. Lett. 15 (2005) 435-438
71. 7 receptor antagonists Bioorg. Med. Chem. Lett. 13 (2003) 4047-4050
72. Baxter, A. et al. (2004) AstraZeneca AB. Adamantane derivatives. US patent number 6242470
73. 7 receptor antagonist, dose-dependently reduces neuropathic pain in the rat. J. Pharmacol. Exp. Ther. 319 (2006) 1376-1385
74. Dombroski, M.A. et al. (2006) Pfizer, Inc. Benzamide inhibitors of the P2X7 receptor. US patent number 7071223
75. Silverstein, S.C. et al. (2006) The Trustees of Columbia University. Method for using phagocytic particles and atp receptors to deliver antigens to MHC class I receptors to induce immunity against microbial pathogens or tumors or to suppress immunity. US patent number 7037500
76. Chae J.J., et al. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 9982-9987
77. Ciana P., et al. The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor. EMBO J. 25 (2006) 4615-4627